泽璟制药-U事件点评:ZG006授权给艾伯维 泽速宁获批上市

甬兴证券有限公司
Jan 25

事件2025 年12 月30 日,泽璟制药与艾伯维集团控股公司就ZG006 的全球开发及商业化签署战略合作与许可选择权协议,公司将获得1 亿美元首付款;基于临床进展的近期里程碑付款及与许可选择相关付款合计最高6,000 万美元,如艾伯维行使许可选择权,泽璟有资格获得最高10.75 亿美元里程碑付款,并就包含ZG006 的产品在大中华区以外的净销售额收取从高个位数到中双位数的阶梯式特许权使用费。核心...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10